Thermo Fisher Scientific reported a 10% increase in Q2 2026 revenue to $11.99 billion and a 13% rise in adjusted EPS to $6.03, surpassing analyst expectations. The company's adjusted operating margin improved to 22.8%, driven by strong growth in its Life Sciences Solutions segment, which grew revenue by 12.6% to $2.82 billion. Following these results, Thermo Fisher raised its full-year financial outlook, citing better customer activity and benefits from recent acquisitions. This strong performance also led RBC Capital to raise its price target for the stock to $580 from $490.
American Express reported Q2 earnings per share of $4.53, surpassing analyst expectations of $4.41. While revenue came in at $15 billion, below the estimated $19.7 billion, increased cardmember spending by 9% drove overall sales and profit growth. Th...
Crédit Agricole Normandie-Seine reported strong first-half 2026 results with record credit and deposit volumes, a 15.2 million euro increase in net banking income, and a 13.9% rise in net profit to 65.1 million euros. The bank's credit portfolio reac...
Virtual Investor Conferences announced that presentations from the July 22-23 Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing for 90 days. Investors can access company materials and schedule one...
Guggenheim lowered its price target for Tractor Supply to $40, citing a Q2 earnings miss with adjusted EPS of $0.81 and sales of $4.5 billion, both below expectations. The company also reported a 1.5% decline in comparable-store sales and a drop in c...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
